BAD HOMBURG, Germany, November 2, 2011 /PRNewswire/ -- Q1-3 2011: - Sales EUR12.1 billion, +2% at actual rates, +5% in constant currency

WINNIPEG, Feb.

APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market under the symbol APPX, today announced that the NASDAQ Global Market has accepted for listing the Contingent Value Rights (CVRs) related to the acquisition of APP by Fresenius Kabi, a business segment of Fresenius SE.

APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market under the symbol APPX, today announced that Fresenius Kabi, a business segment of Fresenius SE, has completed its acquisition of APP. The official close date is September 10, 2008.

APP Pharmaceuticals, Inc. (Nasdaq:APPX) and Fresenius SE (XETRA:FRE) have received confirmation that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of APP Pharmaceuticals by Fresenius Kabi, a business segment of Fresenius SE.